ANI Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary

• ANI Pharmaceuticals, Inc. reported quarterly adjusted earnings of $2.70​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $2.04. The mean expectation of nine analysts for the quarter was for earnings of $2.18 per share. Wall Street expected results to range from $2.02 to $2.33 per share.

• Revenue rose 27.6% to $290.78 million from a year ago; analysts expected $280.20 million.

• ANI Pharmaceuticals, Inc.'s reported EPS for the quarter was $1.51​.

• The company reported quarterly net income of $35.15 million.

• ANI Pharmaceuticals, Inc. shares had fallen by 1.4% this quarter and lost 9.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 13% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for ANI Pharmaceuticals, Inc. is $102.00, about 29.8% above its last closing price of $71.65

This summary was machine generated from LSEG data November 5 at 03:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)